Neuropeptide Theory of Depression: Beyond SSRIs
Neuropeptides & Depression
~30% non-response rate
Approximately 30% of patients with major depressive disorder do not respond adequately to SSRI antidepressants, suggesting pathways beyond serotonin are involved.
Singanwad et al., Neuropeptides, 2025
Singanwad et al., Neuropeptides, 2025
View as imageThe monoamine hypothesis of depression, which frames the disorder as a deficit of serotonin, norepinephrine, or dopamine, has dominated psychiatry for over 60 years. SSRIs and SNRIs work by increasing monoamine availability at synapses. They help many patients. But roughly 30% of people with major depressive disorder do not respond adequately to these drugs.[1] The neuropeptide theory of depression offers an explanation for this treatment gap: the biology of depression extends beyond serotonin into peptide signaling systems that monoamine-targeted drugs barely touch.
Key Takeaways
- NPY is reduced in the cerebrospinal fluid of depressed patients, and a randomized controlled trial of intranasal NPY showed antidepressant effects at a single 6.8 mg dose (Mathe et al., 2020)
- CRF (corticotropin-releasing factor) drives the HPA axis stress response; elevated CRF in the brain is one of the most replicated biological findings in depression (Dedic et al., 2018)
- Substance P antagonists (NK1 receptor blockers) showed antidepressant effects in early trials but failed in larger phase III studies, illustrating the difficulty of translating neuropeptide research to drugs
- Oxytocin and vasopressin balance in the brain influences anxiety and social behavior, with disrupted ratios observed in depression (Neumann and Landgraf, 2012)
- NPY modulates neuroplasticity, neuroinflammation, and HPA axis function through multiple receptor subtypes (Y1, Y2, Y5), each with different effects on mood (Singanwad et al., 2025)
- The endocannabinoid system interacts with neuropeptides like CRF and NPY, suggesting convergent pathways in depression and anxiety (Golyszny et al., 2025)
Why Serotonin Is Not the Whole Story
SSRIs increase serotonin in the synapse within hours. Antidepressant effects take weeks to appear. This temporal disconnect has long suggested that serotonin elevation is a proximal event, not the mechanism of clinical improvement. Downstream changes in gene expression, neuroplasticity, and neuroendocrine function are likely what drives recovery, and neuropeptides are involved in all three.[1]
Neuropeptides differ from classical neurotransmitters in fundamental ways. They are released from dense-core vesicles (not synaptic vesicles), travel farther from the release site through volume transmission, act on G protein-coupled receptors rather than ligand-gated ion channels, and produce slower, longer-lasting effects. They function as neuromodulators, adjusting the gain and tone of neural circuits rather than transmitting point-to-point signals.[3]
More than 100 neuropeptides have been identified in the human brain. Several have been directly implicated in depression through converging lines of evidence: altered levels in the cerebrospinal fluid or blood of depressed patients, effects on mood-related behaviors in animal models, and (in some cases) clinical trial data in humans.
CRF: The Stress Peptide That Drives Depression
Corticotropin-releasing factor (CRF, also called CRH) is the master regulator of the body's stress response. Released from the paraventricular nucleus of the hypothalamus, CRF activates the hypothalamic-pituitary-adrenal (HPA) axis, triggering ACTH release from the pituitary and cortisol release from the adrenal glands.[3]
But CRF does more than drive cortisol. It acts directly on neurons in the amygdala, hippocampus, and prefrontal cortex through two receptor subtypes: CRF1 and CRF2. CRF1 activation in the amygdala promotes anxiety and fear behaviors. CRF2, activated primarily by the related peptides urocortins 1, 2, and 3, appears to play a role in stress recovery and coping.[4]
Elevated CRF in the brain is one of the most replicated biological findings in depression. Post-mortem studies show increased CRF immunoreactivity in the hypothalamus and cortex of suicide victims. CSF levels of CRF are elevated in depressed patients and normalize with successful treatment. The CRF system's hyperactivity in depression is not simply a consequence of stress exposure; it appears to be a core feature of the disease biology in many patients.[3]
Dedic and colleagues reviewed the CRF family in 2018, noting that CRF acts both as a hormonal signal (through the HPA axis) and as a neurotransmitter (through direct neural circuits). This dual role means CRF dysregulation affects mood through at least two mechanisms: chronic cortisol elevation that damages hippocampal neurons, and direct overactivation of anxiety circuits in the amygdala.[3] For more on CRF's role in the stress-depression connection, see the dedicated article.
CRF1 receptor antagonists entered clinical development as potential antidepressants. Early results were mixed: some compounds showed efficacy in subsets of patients with elevated stress hormones, but liver toxicity and variable pharmacokinetics plagued development. No CRF1 antagonist has reached market approval for depression.
NPY: The Resilience Peptide
If CRF is the "stress accelerator," neuropeptide Y (NPY) is the "stress brake." NPY is one of the most abundant neuropeptides in the mammalian brain, with particularly high concentrations in the amygdala, hippocampus, and hypothalamus. It acts through multiple receptor subtypes (Y1, Y2, Y4, Y5), each with distinct effects on mood, anxiety, and feeding behavior.[1]
NPY levels are consistently reduced in the cerebrospinal fluid of patients with major depressive disorder. Yuan and colleagues reported in 2026 that serum NPY levels differ between male and female depressed patients, and between premenopausal and postmenopausal women with MDD, suggesting sex-specific regulation of this peptide in depression.[5]
Singanwad and colleagues reviewed NPY's multifaceted role in 2025, emphasizing three mechanisms relevant to treatment-resistant depression: NPY promotes neuroplasticity (the brain's ability to rewire), suppresses neuroinflammation (which is elevated in many depressed patients), and directly counteracts HPA axis hyperactivity by inhibiting CRF release. Through Y1 receptors, NPY produces anxiolytic and antidepressant effects. Through Y2 receptors (which are presynaptic autoreceptors), NPY modulates its own release. The Y5 receptor's role remains less clear but appears involved in feeding and anxiety circuits.[1]
The most direct clinical evidence came from Mathe and colleagues in 2020: a randomized, double-blind, placebo-controlled trial of intranasal NPY in patients with major depressive disorder. A single 6.8 mg dose of intranasal NPY produced a significant reduction in depression scores compared to placebo. The effect was measurable within days and persisted for the duration of the observation period. While the trial was small and preliminary, it provided the first human proof-of-concept that directly supplementing a deficient neuropeptide can produce antidepressant effects.[2]
NPY's connection to stress resilience extends beyond depression. Military research has shown that special forces soldiers with higher NPY levels cope better with extreme stress, and NPY is the focus of research into why some people handle trauma better than others.
Substance P: The Failed Promise and What It Taught Us
Substance P, an 11-amino-acid neuropeptide that acts through the neurokinin-1 (NK1) receptor, received enormous attention after Kramer and colleagues published a landmark 1998 trial in Science showing that the NK1 antagonist MK-869 (aprepitant) had antidepressant effects comparable to paroxetine (an SSRI), with fewer sexual side effects.
The finding was remarkable because it suggested depression could be treated by targeting a completely different signaling system than monoamines. Substance P is found in brain regions associated with mood regulation (amygdala, hypothalamus, periaqueductal gray), and NK1 receptors are widely expressed in emotion-processing circuits.
But subsequent phase III trials of NK1 antagonists for depression failed to replicate the initial positive results consistently. Multiple compounds were tested; results were inconsistent across studies and doses. Merck eventually abandoned aprepitant for depression (though it was approved for chemotherapy-induced nausea, where NK1 blockade works through a different mechanism). For a deeper analysis, see substance P antagonists for depression: why pharma tried and struggled.
The substance P experience illustrates a recurring challenge in neuropeptide drug development: peptide signaling is redundant and context-dependent. Blocking one receptor in one neuropeptide system may be compensated by parallel pathways. The brain's mood circuitry is not a single wire; it is a network.
Oxytocin and Vasopressin: Social Peptides and Mood
Oxytocin and vasopressin, two closely related nine-amino-acid peptides, modulate social behavior, trust, attachment, and stress responses. Their relevance to depression lies in the social dimension of the illness: withdrawal, isolation, anhedonia in social contexts, and impaired bonding.
Neumann and Landgraf reviewed the balance of brain oxytocin and vasopressin in 2012, demonstrating that the ratio between these two peptides influences anxiety and depression-like behaviors. Oxytocin generally produces anxiolytic and prosocial effects; vasopressin tends to promote anxiety and aggression. In depressed patients, this balance may be disrupted, with reduced oxytocin signaling and relatively increased vasopressin tone.[6]
Zhu and colleagues conducted a systematic review of randomized controlled trials of oxytocin for postpartum depression in 2023 and found mixed results. Some studies showed improvement in mood scores; others showed no benefit. The inconsistency may relate to dosing, route of administration (intranasal vs. intravenous), and the heterogeneity of postpartum depression itself.[7]
The Convergence Problem: Why Single-Target Approaches Fail
Golyszny and colleagues reviewed the interplay between endocannabinoids and neuropeptides in depression and anxiety in 2025, finding that the endocannabinoid system modulates CRF and NPY signaling at multiple levels. CB1 receptor activation can suppress CRF release from the amygdala and enhance NPY signaling in the hippocampus, providing an anti-stress, antidepressant-like effect. This convergence suggests that depression involves dysregulation of multiple interconnected peptide systems, not a single broken pathway.[8]
This interconnection explains a core prediction of the neuropeptide theory: why SSRIs work for some patients and not others. If a patient's depression is primarily driven by CRF hyperactivity and HPA axis dysregulation, an SSRI may help indirectly (serotonin does modulate the HPA axis) but will not address the root cause. If the depression involves NPY deficiency and impaired stress resilience, increasing serotonin will not restore NPY levels. The neuropeptide theory predicts that depression is biologically heterogeneous, with different peptide systems predominating in different patients.[1]
Dyndal and colleagues reviewed metabolic modulators in depression in 2025, noting that GLP-1 receptor agonists and other metabolic peptides show antidepressant effects in preclinical models, potentially through anti-inflammatory and neuroprotective mechanisms rather than direct monoamine modulation.[9] This adds yet another peptide system to the depression landscape.
What Neuropeptide Theory Explains That SSRIs Cannot
The neuropeptide framework accounts for several clinical observations that the monoamine hypothesis struggles with:
Treatment resistance. If depression in a given patient is driven by CRF overactivity or NPY deficiency rather than serotonin deficit, serotonin-targeting drugs will produce limited benefit. The 30% non-response rate to SSRIs may reflect the proportion of patients whose depression has a primarily neuropeptide-driven etiology.
Stress sensitivity. CRF and NPY provide a biological mechanism for the observation that stressful life events trigger and sustain depression. The monoamine hypothesis has no direct explanation for why stress causes depression; the neuropeptide theory has several.
Sex differences. NPY levels and their relationship to appetite and mood differ between males and females, and between premenopausal and postmenopausal women.[5] Women are twice as likely to develop depression as men. Neuropeptide systems with sex-dependent regulation offer a biological substrate for this disparity.
Somatic symptoms. Depression is not only a mood disorder; it involves appetite changes, sleep disruption, pain sensitivity, and immune dysregulation. NPY regulates appetite and circadian rhythms. CRF modulates the immune system. Substance P mediates pain transmission. Neuropeptides are expressed throughout the body, not just in the brain, and their dysregulation could explain depression's multi-system presentation.
Comorbidity with anxiety. CRF1 activation drives both anxiety and depression. The high comorbidity between these conditions makes sense if they share a common neuropeptide substrate. Selank clinical studies also explore neuropeptide approaches to comorbid anxiety.
The Bottom Line
The neuropeptide theory of depression proposes that mood disorders involve dysregulation of peptide signaling systems, including CRF, NPY, substance P, oxytocin, and vasopressin, that SSRIs do not directly target. CRF overactivity drives the stress-depression axis. NPY deficiency impairs stress resilience, neuroplasticity, and anti-inflammatory defenses. Substance P antagonists showed initial promise but failed in large trials, revealing the redundancy of peptide networks. A 2020 randomized trial of intranasal NPY provided the first human proof that correcting a neuropeptide deficit can produce antidepressant effects. The theory predicts that depression is biologically heterogeneous, and future treatments will need to match the specific peptide dysfunction to the individual patient.